Xtant Medical (NYSEAMERICAN:XTNT) raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter revenue...
Raises full-year 2026 revenue guidance to a range of $101-$105 million
BELGRADE, Mont. , May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,...
BELGRADE, Mont. , May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,...
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products
BELGRADE, Mont. , April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced...
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year
BELGRADE, Mont. , March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic...
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments
BELGRADE, Mont. , Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal,...